世界のアンチセンス・RNAi治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Antisense & RNAi Therapeutics Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z0411 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、125ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、アンチセンス・RNAi治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（RNA干渉、SiRNA、MiRNA、アンチセンスRNA）、用途別市場規模（腫瘍、心臓血管、腎臓、神経変性、呼吸器、遺伝、感染症）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・アンチセンス・RNAi治療の市場動向 ・企業の競争状況、市場シェア ・アンチセンス・RNAi治療の種類別市場規模（RNA干渉、SiRNA、MiRNA、アンチセンスRNA） ・アンチセンス・RNAi治療の用途別市場規模（腫瘍、心臓血管、腎臓、神経変性、呼吸器、遺伝、感染症） ・アンチセンス・RNAi治療の北米市場規模2016-2027（アメリカ、カナダ） ・アンチセンス・RNAi治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・アンチセンス・RNAi治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・アンチセンス・RNAi治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・アンチセンス・RNAi治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Glaxo Smith Kline、Sanofi Aventis / Genzyme、Isis Pharmaceuticals/ Ionis Pharmaceuticals、Arbutus Biopharma Ltd.、Silence Therapeutics、Bio-Path Holdings Inc.、Calando Pharmaceuticals、ICo Therapeutics、Quark Pharmaceuticals、Rexhan Pharmaceuticals、Biomarin/Prosensa、Regulus Therapeutics、Rxi Pharmaceuticals、Silenseed、Dicerna Pharmaceuticals、Sirnaomics Inc.） ・結論

Antisense therapy is a form of treatment for genetic disorders or infections. When the genetic sequence of a particular gene is known to be causative of a particular disease, it is possible to synthesize a strand of nucleic acid (DNA, RNA or a chemical analogue) that will bind to the messenger RNA (mRNA) produced by that gene and inactivate it, effectively turning that gene “off”.
North America is a key market, with U.S. reflecting a number of RNAi therapeutics currently in developmental pipelines. A number of biotechnology companies have made considerably high investments for RNAi therapeutic development. Big pharmaceutical developers have entered into collaboration agreements or licensing deals with a number of smaller firms in an attempt to capitalize on the expected revenue growth of this market.

Market Analysis and Insights: Global Antisense & RNAi Therapeutics Market
The global Antisense & RNAi Therapeutics market size is projected to reach US$ 1287.2 million by 2026, from US$ 958.5 million in 2019, at a CAGR of 4.3% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Antisense & RNAi Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Antisense & RNAi Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Antisense & RNAi Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Antisense & RNAi Therapeutics market.

Global Antisense & RNAi Therapeutics Scope and Market Size
Antisense & RNAi Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Antisense & RNAi Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
RNA interference
SiRNA
MiRNA
Antisense RNA

Segment by Application
Oncology
Cardiovascular
Renal
Neurodegenerative
Respiratory
Genetic
Infectious Diseases

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Glaxo Smith Kline
Sanofi Aventis / Genzyme
Isis Pharmaceuticals/ Ionis Pharmaceuticals
Arbutus Biopharma Ltd.
Silence Therapeutics
Bio-Path Holdings Inc.
Calando Pharmaceuticals
ICo Therapeutics
Quark Pharmaceuticals
Arbutus Biopharma Ltd.
Silence Therapeutics
Regulus Therapeutics
Rxi Pharmaceuticals
Silenseed

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antisense & RNAi Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 RNA interference
1.2.3 SiRNA
1.2.4 MiRNA
1.2.5 Antisense RNA
1.3 Market by Application
1.3.1 Global Antisense & RNAi Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Oncology
1.3.3 Cardiovascular
1.3.4 Renal
1.3.5 Neurodegenerative
1.3.6 Respiratory
1.3.7 Genetic
1.3.8 Infectious Diseases
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Antisense & RNAi Therapeutics Market Perspective (2016-2027)
2.2 Antisense & RNAi Therapeutics Growth Trends by Regions
2.2.1 Antisense & RNAi Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Antisense & RNAi Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Antisense & RNAi Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Antisense & RNAi Therapeutics Industry Dynamic
2.3.1 Antisense & RNAi Therapeutics Market Trends
2.3.2 Antisense & RNAi Therapeutics Market Drivers
2.3.3 Antisense & RNAi Therapeutics Market Challenges
2.3.4 Antisense & RNAi Therapeutics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Antisense & RNAi Therapeutics Players by Revenue
3.1.1 Global Top Antisense & RNAi Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Antisense & RNAi Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Antisense & RNAi Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Antisense & RNAi Therapeutics Revenue
3.4 Global Antisense & RNAi Therapeutics Market Concentration Ratio
3.4.1 Global Antisense & RNAi Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antisense & RNAi Therapeutics Revenue in 2020
3.5 Antisense & RNAi Therapeutics Key Players Head office and Area Served
3.6 Key Players Antisense & RNAi Therapeutics Product Solution and Service
3.7 Date of Enter into Antisense & RNAi Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Antisense & RNAi Therapeutics Breakdown Data by Type
4.1 Global Antisense & RNAi Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Antisense & RNAi Therapeutics Forecasted Market Size by Type (2022-2027)

5 Antisense & RNAi Therapeutics Breakdown Data by Application
5.1 Global Antisense & RNAi Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Antisense & RNAi Therapeutics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Antisense & RNAi Therapeutics Market Size (2016-2027)
6.2 North America Antisense & RNAi Therapeutics Market Size by Type
6.2.1 North America Antisense & RNAi Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Antisense & RNAi Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Antisense & RNAi Therapeutics Market Size by Type (2016-2027)
6.3 North America Antisense & RNAi Therapeutics Market Size by Application
6.3.1 North America Antisense & RNAi Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Antisense & RNAi Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Antisense & RNAi Therapeutics Market Size by Application (2016-2027)
6.4 North America Antisense & RNAi Therapeutics Market Size by Country
6.4.1 North America Antisense & RNAi Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Antisense & RNAi Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Antisense & RNAi Therapeutics Market Size (2016-2027)
7.2 Europe Antisense & RNAi Therapeutics Market Size by Type
7.2.1 Europe Antisense & RNAi Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Antisense & RNAi Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Antisense & RNAi Therapeutics Market Size by Type (2016-2027)
7.3 Europe Antisense & RNAi Therapeutics Market Size by Application
7.3.1 Europe Antisense & RNAi Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Antisense & RNAi Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Antisense & RNAi Therapeutics Market Size by Application (2016-2027)
7.4 Europe Antisense & RNAi Therapeutics Market Size by Country
7.4.1 Europe Antisense & RNAi Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Antisense & RNAi Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Antisense & RNAi Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Antisense & RNAi Therapeutics Market Size by Type
8.2.1 Asia-Pacific Antisense & RNAi Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Antisense & RNAi Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Antisense & RNAi Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Antisense & RNAi Therapeutics Market Size by Application
8.3.1 Asia-Pacific Antisense & RNAi Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Antisense & RNAi Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Antisense & RNAi Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Antisense & RNAi Therapeutics Market Size by Region
8.4.1 Asia-Pacific Antisense & RNAi Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Antisense & RNAi Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Antisense & RNAi Therapeutics Market Size (2016-2027)
9.2 Latin America Antisense & RNAi Therapeutics Market Size by Type
9.2.1 Latin America Antisense & RNAi Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Antisense & RNAi Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Antisense & RNAi Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Antisense & RNAi Therapeutics Market Size by Application
9.3.1 Latin America Antisense & RNAi Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Antisense & RNAi Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Antisense & RNAi Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Antisense & RNAi Therapeutics Market Size by Country
9.4.1 Latin America Antisense & RNAi Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Antisense & RNAi Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Antisense & RNAi Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Antisense & RNAi Therapeutics Market Size by Type
10.2.1 Middle East & Africa Antisense & RNAi Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Antisense & RNAi Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Antisense & RNAi Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Antisense & RNAi Therapeutics Market Size by Application
10.3.1 Middle East & Africa Antisense & RNAi Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Antisense & RNAi Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Antisense & RNAi Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Antisense & RNAi Therapeutics Market Size by Country
10.4.1 Middle East & Africa Antisense & RNAi Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Antisense & RNAi Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Glaxo Smith Kline
11.1.1 Glaxo Smith Kline Company Details
11.1.2 Glaxo Smith Kline Business Overview
11.1.3 Glaxo Smith Kline Antisense & RNAi Therapeutics Introduction
11.1.4 Glaxo Smith Kline Revenue in Antisense & RNAi Therapeutics Business (2016-2021)
11.1.5 Glaxo Smith Kline Recent Development
11.2 Sanofi Aventis / Genzyme
11.2.1 Sanofi Aventis / Genzyme Company Details
11.2.2 Sanofi Aventis / Genzyme Business Overview
11.2.3 Sanofi Aventis / Genzyme Antisense & RNAi Therapeutics Introduction
11.2.4 Sanofi Aventis / Genzyme Revenue in Antisense & RNAi Therapeutics Business (2016-2021)
11.2.5 Sanofi Aventis / Genzyme Recent Development
11.3 Isis Pharmaceuticals/ Ionis Pharmaceuticals
11.3.1 Isis Pharmaceuticals/ Ionis Pharmaceuticals Company Details
11.3.2 Isis Pharmaceuticals/ Ionis Pharmaceuticals Business Overview
11.3.3 Isis Pharmaceuticals/ Ionis Pharmaceuticals Antisense & RNAi Therapeutics Introduction
11.3.4 Isis Pharmaceuticals/ Ionis Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2016-2021)
11.3.5 Isis Pharmaceuticals/ Ionis Pharmaceuticals Recent Development
11.4 Arbutus Biopharma Ltd.
11.4.1 Arbutus Biopharma Ltd. Company Details
11.4.2 Arbutus Biopharma Ltd. Business Overview
11.4.3 Arbutus Biopharma Ltd. Antisense & RNAi Therapeutics Introduction
11.4.4 Arbutus Biopharma Ltd. Revenue in Antisense & RNAi Therapeutics Business (2016-2021)
11.4.5 Arbutus Biopharma Ltd. Recent Development
11.5 Silence Therapeutics
11.5.1 Silence Therapeutics Company Details
11.5.2 Silence Therapeutics Business Overview
11.5.3 Silence Therapeutics Antisense & RNAi Therapeutics Introduction
11.5.4 Silence Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2016-2021)
11.5.5 Silence Therapeutics Recent Development
11.6 Bio-Path Holdings Inc.
11.6.1 Bio-Path Holdings Inc. Company Details
11.6.2 Bio-Path Holdings Inc. Business Overview
11.6.3 Bio-Path Holdings Inc. Antisense & RNAi Therapeutics Introduction
11.6.4 Bio-Path Holdings Inc. Revenue in Antisense & RNAi Therapeutics Business (2016-2021)
11.6.5 Bio-Path Holdings Inc. Recent Development
11.7 Calando Pharmaceuticals
11.7.1 Calando Pharmaceuticals Company Details
11.7.2 Calando Pharmaceuticals Business Overview
11.7.3 Calando Pharmaceuticals Antisense & RNAi Therapeutics Introduction
11.7.4 Calando Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2016-2021)
11.7.5 Calando Pharmaceuticals Recent Development
11.8 ICo Therapeutics
11.8.1 ICo Therapeutics Company Details
11.8.2 ICo Therapeutics Business Overview
11.8.3 ICo Therapeutics Antisense & RNAi Therapeutics Introduction
11.8.4 ICo Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2016-2021)
11.8.5 ICo Therapeutics Recent Development
11.9 Quark Pharmaceuticals
11.9.1 Quark Pharmaceuticals Company Details
11.9.2 Quark Pharmaceuticals Business Overview
11.9.3 Quark Pharmaceuticals Antisense & RNAi Therapeutics Introduction
11.9.4 Quark Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2016-2021)
11.9.5 Quark Pharmaceuticals Recent Development
11.10 Rexhan Pharmaceuticals
11.10.1 Rexhan Pharmaceuticals Company Details
11.10.2 Rexhan Pharmaceuticals Business Overview
11.10.3 Rexhan Pharmaceuticals Antisense & RNAi Therapeutics Introduction
11.10.4 Rexhan Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2016-2021)
11.10.5 Rexhan Pharmaceuticals Recent Development
11.11 Biomarin/Prosensa
11.11.1 Biomarin/Prosensa Company Details
11.11.2 Biomarin/Prosensa Business Overview
11.11.3 Biomarin/Prosensa Antisense & RNAi Therapeutics Introduction
11.11.4 Biomarin/Prosensa Revenue in Antisense & RNAi Therapeutics Business (2016-2021)
11.11.5 Biomarin/Prosensa Recent Development
11.12 Regulus Therapeutics
11.12.1 Regulus Therapeutics Company Details
11.12.2 Regulus Therapeutics Business Overview
11.12.3 Regulus Therapeutics Antisense & RNAi Therapeutics Introduction
11.12.4 Regulus Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2016-2021)
11.12.5 Regulus Therapeutics Recent Development
11.13 Rxi Pharmaceuticals
11.13.1 Rxi Pharmaceuticals Company Details
11.13.2 Rxi Pharmaceuticals Business Overview
11.13.3 Rxi Pharmaceuticals Antisense & RNAi Therapeutics Introduction
11.13.4 Rxi Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2016-2021)
11.13.5 Rxi Pharmaceuticals Recent Development
11.14 Silenseed
11.14.1 Silenseed Company Details
11.14.2 Silenseed Business Overview
11.14.3 Silenseed Antisense & RNAi Therapeutics Introduction
11.14.4 Silenseed Revenue in Antisense & RNAi Therapeutics Business (2016-2021)
11.14.5 Silenseed Recent Development
11.15 Dicerna Pharmaceuticals
11.15.1 Dicerna Pharmaceuticals Company Details
11.15.2 Dicerna Pharmaceuticals Business Overview
11.15.3 Dicerna Pharmaceuticals Antisense & RNAi Therapeutics Introduction
11.15.4 Dicerna Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2016-2021)
11.15.5 Dicerna Pharmaceuticals Recent Development
11.16 Sirnaomics Inc.
11.16.1 Sirnaomics Inc. Company Details
11.16.2 Sirnaomics Inc. Business Overview
11.16.3 Sirnaomics Inc. Antisense & RNAi Therapeutics Introduction
11.16.4 Sirnaomics Inc. Revenue in Antisense & RNAi Therapeutics Business (2016-2021)
11.16.5 Sirnaomics Inc. Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Antisense & RNAi Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of RNA interference
Table 3. Key Players of SiRNA
Table 4. Key Players of MiRNA
Table 5. Key Players of Antisense RNA
Table 6. Global Antisense & RNAi Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Antisense & RNAi Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Antisense & RNAi Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Antisense & RNAi Therapeutics Market Share by Regions (2016-2021)
Table 10. Global Antisense & RNAi Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Antisense & RNAi Therapeutics Market Share by Regions (2022-2027)
Table 12. Antisense & RNAi Therapeutics Market Trends
Table 13. Antisense & RNAi Therapeutics Market Drivers
Table 14. Antisense & RNAi Therapeutics Market Challenges
Table 15. Antisense & RNAi Therapeutics Market Restraints
Table 16. Global Antisense & RNAi Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Antisense & RNAi Therapeutics Market Share by Players (2016-2021)
Table 18. Global Top Antisense & RNAi Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antisense & RNAi Therapeutics as of 2020)
Table 19. Ranking of Global Top Antisense & RNAi Therapeutics Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Antisense & RNAi Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Antisense & RNAi Therapeutics Product Solution and Service
Table 23. Date of Enter into Antisense & RNAi Therapeutics Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Antisense & RNAi Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Antisense & RNAi Therapeutics Revenue Market Share by Type (2016-2021)
Table 27. Global Antisense & RNAi Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Antisense & RNAi Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Antisense & RNAi Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Antisense & RNAi Therapeutics Revenue Market Share by Application (2016-2021)
Table 31. Global Antisense & RNAi Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Antisense & RNAi Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Antisense & RNAi Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Antisense & RNAi Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Antisense & RNAi Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Antisense & RNAi Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Antisense & RNAi Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Antisense & RNAi Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Antisense & RNAi Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Antisense & RNAi Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Antisense & RNAi Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Antisense & RNAi Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Antisense & RNAi Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Antisense & RNAi Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Antisense & RNAi Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Antisense & RNAi Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Antisense & RNAi Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Antisense & RNAi Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Antisense & RNAi Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Antisense & RNAi Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Antisense & RNAi Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Antisense & RNAi Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Antisense & RNAi Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Antisense & RNAi Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Antisense & RNAi Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Antisense & RNAi Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Antisense & RNAi Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Antisense & RNAi Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Antisense & RNAi Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Antisense & RNAi Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Antisense & RNAi Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Antisense & RNAi Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 63. Glaxo Smith Kline Company Details
Table 64. Glaxo Smith Kline Business Overview
Table 65. Glaxo Smith Kline Antisense & RNAi Therapeutics Product
Table 66. Glaxo Smith Kline Revenue in Antisense & RNAi Therapeutics Business (2016-2021) & (US$ Million)
Table 67. Glaxo Smith Kline Recent Development
Table 68. Sanofi Aventis / Genzyme Company Details
Table 69. Sanofi Aventis / Genzyme Business Overview
Table 70. Sanofi Aventis / Genzyme Antisense & RNAi Therapeutics Product
Table 71. Sanofi Aventis / Genzyme Revenue in Antisense & RNAi Therapeutics Business (2016-2021) & (US$ Million)
Table 72. Sanofi Aventis / Genzyme Recent Development
Table 73. Isis Pharmaceuticals/ Ionis Pharmaceuticals Company Details
Table 74. Isis Pharmaceuticals/ Ionis Pharmaceuticals Business Overview
Table 75. Isis Pharmaceuticals/ Ionis Pharmaceuticals Antisense & RNAi Therapeutics Product
Table 76. Isis Pharmaceuticals/ Ionis Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2016-2021) & (US$ Million)
Table 77. Isis Pharmaceuticals/ Ionis Pharmaceuticals Recent Development
Table 78. Arbutus Biopharma Ltd. Company Details
Table 79. Arbutus Biopharma Ltd. Business Overview
Table 80. Arbutus Biopharma Ltd. Antisense & RNAi Therapeutics Product
Table 81. Arbutus Biopharma Ltd. Revenue in Antisense & RNAi Therapeutics Business (2016-2021) & (US$ Million)
Table 82. Arbutus Biopharma Ltd. Recent Development
Table 83. Silence Therapeutics Company Details
Table 84. Silence Therapeutics Business Overview
Table 85. Silence Therapeutics Antisense & RNAi Therapeutics Product
Table 86. Silence Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2016-2021) & (US$ Million)
Table 87. Silence Therapeutics Recent Development
Table 88. Bio-Path Holdings Inc. Company Details
Table 89. Bio-Path Holdings Inc. Business Overview
Table 90. Bio-Path Holdings Inc. Antisense & RNAi Therapeutics Product
Table 91. Bio-Path Holdings Inc. Revenue in Antisense & RNAi Therapeutics Business (2016-2021) & (US$ Million)
Table 92. Bio-Path Holdings Inc. Recent Development
Table 93. Calando Pharmaceuticals Company Details
Table 94. Calando Pharmaceuticals Business Overview
Table 95. Calando Pharmaceuticals Antisense & RNAi Therapeutics Product
Table 96. Calando Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2016-2021) & (US$ Million)
Table 97. Calando Pharmaceuticals Recent Development
Table 98. ICo Therapeutics Company Details
Table 99. ICo Therapeutics Business Overview
Table 100. ICo Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2016-2021) & (US$ Million)
Table 101. ICo Therapeutics Recent Development
Table 102. Quark Pharmaceuticals Company Details
Table 103. Quark Pharmaceuticals Business Overview
Table 104. Quark Pharmaceuticals Antisense & RNAi Therapeutics Product
Table 105. Quark Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2016-2021) & (US$ Million)
Table 106. Quark Pharmaceuticals Recent Development
Table 107. Rexhan Pharmaceuticals Company Details
Table 108. Rexhan Pharmaceuticals Business Overview
Table 109. Rexhan Pharmaceuticals Antisense & RNAi Therapeutics Product
Table 110. Rexhan Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2016-2021) & (US$ Million)
Table 111. Rexhan Pharmaceuticals Recent Development
Table 112. Biomarin/Prosensa Company Details
Table 113. Biomarin/Prosensa Business Overview
Table 114. Biomarin/Prosensa Antisense & RNAi Therapeutics Product
Table 115. Biomarin/Prosensa Revenue in Antisense & RNAi Therapeutics Business (2016-2021) & (US$ Million)
Table 116. Biomarin/Prosensa Recent Development
Table 117. Regulus Therapeutics Company Details
Table 118. Regulus Therapeutics Business Overview
Table 119. Regulus Therapeutics Antisense & RNAi Therapeutics Product
Table 120. Regulus Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2016-2021) & (US$ Million)
Table 121. Regulus Therapeutics Recent Development
Table 122. Rxi Pharmaceuticals Company Details
Table 123. Rxi Pharmaceuticals Business Overview
Table 124. Rxi Pharmaceuticals Antisense & RNAi Therapeutics Product
Table 125. Rxi Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2016-2021) & (US$ Million)
Table 126. Rxi Pharmaceuticals Recent Development
Table 127. Silenseed Company Details
Table 128. Silenseed Business Overview
Table 129. Silenseed Antisense & RNAi Therapeutics Product
Table 130. Silenseed Revenue in Antisense & RNAi Therapeutics Business (2016-2021) & (US$ Million)
Table 131. Silenseed Recent Development
Table 132. Dicerna Pharmaceuticals Company Details
Table 133. Dicerna Pharmaceuticals Business Overview
Table 134. Dicerna Pharmaceuticals Antisense & RNAi Therapeutics Product
Table 135. Dicerna Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2016-2021) & (US$ Million)
Table 136. Dicerna Pharmaceuticals Recent Development
Table 137. Sirnaomics Inc. Company Details
Table 138. Sirnaomics Inc. Business Overview
Table 139. Sirnaomics Inc. Antisense & RNAi Therapeutics Product
Table 140. Sirnaomics Inc. Revenue in Antisense & RNAi Therapeutics Business (2016-2021) & (US$ Million)
Table 141. Sirnaomics Inc. Recent Development
Table 142. Research Programs/Design for This Report
Table 143. Key Data Information from Secondary Sources
Table 144. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Antisense & RNAi Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. RNA interference Features
Figure 3. SiRNA Features
Figure 4. MiRNA Features
Figure 5. Antisense RNA Features
Figure 6. Global Antisense & RNAi Therapeutics Market Share by Application: 2020 VS 2027
Figure 7. Oncology Case Studies
Figure 8. Cardiovascular Case Studies
Figure 9. Renal Case Studies
Figure 10. Neurodegenerative Case Studies
Figure 11. Respiratory Case Studies
Figure 12. Genetic Case Studies
Figure 13. Infectious Diseases Case Studies
Figure 14. Antisense & RNAi Therapeutics Report Years Considered
Figure 15. Global Antisense & RNAi Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 16. Global Antisense & RNAi Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 17. Global Antisense & RNAi Therapeutics Market Share by Regions: 2020 VS 2027
Figure 18. Global Antisense & RNAi Therapeutics Market Share by Regions (2022-2027)
Figure 19. Global Antisense & RNAi Therapeutics Market Share by Players in 2020
Figure 20. Global Top Antisense & RNAi Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antisense & RNAi Therapeutics as of 2020
Figure 21. The Top 10 and 5 Players Market Share by Antisense & RNAi Therapeutics Revenue in 2020
Figure 22. Global Antisense & RNAi Therapeutics Revenue Market Share by Type (2016-2021)
Figure 23. Global Antisense & RNAi Therapeutics Revenue Market Share by Type (2022-2027)
Figure 24. North America Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. North America Antisense & RNAi Therapeutics Market Share by Type (2016-2027)
Figure 26. North America Antisense & RNAi Therapeutics Market Share by Application (2016-2027)
Figure 27. North America Antisense & RNAi Therapeutics Market Share by Country (2016-2027)
Figure 28. United States Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Canada Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Europe Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Europe Antisense & RNAi Therapeutics Market Share by Type (2016-2027)
Figure 32. Europe Antisense & RNAi Therapeutics Market Share by Application (2016-2027)
Figure 33. Europe Antisense & RNAi Therapeutics Market Share by Country (2016-2027)
Figure 34. Germany Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. France Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. U.K. Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Italy Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Russia Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Nordic Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Asia-Pacific Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Asia-Pacific Antisense & RNAi Therapeutics Market Share by Type (2016-2027)
Figure 42. Asia-Pacific Antisense & RNAi Therapeutics Market Share by Application (2016-2027)
Figure 43. Asia-Pacific Antisense & RNAi Therapeutics Market Share by Region (2016-2027)
Figure 44. China Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Japan Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. South Korea Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Southeast Asia Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. India Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Australia Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Latin America Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Latin America Antisense & RNAi Therapeutics Market Share by Type (2016-2027)
Figure 52. Latin America Antisense & RNAi Therapeutics Market Share by Application (2016-2027)
Figure 53. Latin America Antisense & RNAi Therapeutics Market Share by Country (2016-2027)
Figure 54. Mexico Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Brazil Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Middle East & Africa Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Middle East & Africa Antisense & RNAi Therapeutics Market Share by Type (2016-2027)
Figure 58. Middle East & Africa Antisense & RNAi Therapeutics Market Share by Application (2016-2027)
Figure 59. Middle East & Africa Antisense & RNAi Therapeutics Market Share by Country (2016-2027)
Figure 60. Turkey Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. Saudi Arabia Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 62. UAE Antisense & RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 63. Glaxo Smith Kline Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2016-2021)
Figure 64. Sanofi Aventis / Genzyme Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2016-2021)
Figure 65. Isis Pharmaceuticals/ Ionis Pharmaceuticals Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2016-2021)
Figure 66. Arbutus Biopharma Ltd. Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2016-2021)
Figure 67. Silence Therapeutics Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2016-2021)
Figure 68. Bio-Path Holdings Inc. Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2016-2021)
Figure 69. Calando Pharmaceuticals Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2016-2021)
Figure 70. ICo Therapeutics Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2016-2021)
Figure 71. Quark Pharmaceuticals Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2016-2021)
Figure 72. Rexhan Pharmaceuticals Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2016-2021)
Figure 73. Biomarin/Prosensa Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2016-2021)
Figure 74. Regulus Therapeutics Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2016-2021)
Figure 75. Rxi Pharmaceuticals Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2016-2021)
Figure 76. Silenseed Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2016-2021)
Figure 77. Dicerna Pharmaceuticals Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2016-2021)
Figure 78. Sirnaomics Inc. Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2016-2021)
Figure 79. Bottom-up and Top-down Approaches for This Report
Figure 80. Data Triangulation
Figure 81. Key Executives Interviewed

---